References

Ding H, Xu J, Lin Z, et al. Minimal residual disease in multiple myeloma: Current status. Biomark Res. 2021;9(1):75. doi:10.1186/s40364-021-00328-2
National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma. Version 5.2022. Published March 9, 2022. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi:10.3322/caac.21708
Raje NS, Anaissie E, Kumar SK, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: A report from the International Myeloma Working Group. Lancet Haematol. 2022;9(2):e143-e161. doi:10.1016/S2352-3026(21)00283-0
Zhang Z, Liu X, Zhao L, et al. A review on the treatment of multiple myeloma with small molecular agents in the past five years. Eur J Med Chem. 2022;229:114053. doi:10.1016/j.ejmech.2021.114053
Yang Y, Li Y, Gu H, Dong M, Cai Z. Emerging agents and regimens for multiple myeloma. J Hematol Oncol. 2020;13(1):150. doi:10.1186/s13045-020-00980-5
Lancman G, Sastow DL, Cho HJ, et al. Bispecific antibodies in multiple myeloma: Present and future. Blood Cancer Discov. 2021;2(5):423-433. doi:10.1158/2643-3230.BCD-21-0028

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers